Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Non-Current Debt for 10 consecutive years, with $339.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 189.09% to $339.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $339.9 million through Dec 2025, up 189.09% year-over-year, with the annual reading at $339.9 million for FY2025, 189.09% up from the prior year.
  • Non-Current Debt for Q4 2025 was $339.9 million at Madrigal Pharmaceuticals, roughly flat from $339.8 million in the prior quarter.
  • The five-year high for Non-Current Debt was $339.9 million in Q4 2025, with the low at $48.7 million in Q2 2022.
  • Average Non-Current Debt over 4 years is $129.6 million, with a median of $116.1 million recorded in 2024.
  • Peak annual rise in Non-Current Debt hit 190.17% in 2025, while the deepest fall reached 1.52% in 2025.
  • Over 4 years, Non-Current Debt stood at $49.3 million in 2022, then soared by 134.29% to $115.5 million in 2023, then rose by 1.81% to $117.6 million in 2024, then skyrocketed by 189.09% to $339.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $339.9 million, $339.8 million, and $118.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.